| Next 10 |
Ad
AGEN News and Press Agenus Inc.
-
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q2 2022 Earnings Call Transcript
-
Agenus Inc. (AGEN) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Ethan Lovell - Chief of External Affairs & Communications Officer Garo Armen - Chairman & Chief Executive Officer Christine Klaskin - Vice President-Finan...
-
Agenus press release ( NASDAQ: AGEN ): Q2 GAAP EPS of -$0.17. Revenue of $20.93M (+95.1% Y/Y). The company ended second quarter 2022 with a cash and short-term investment balance of $238 million as compared to $263 million and $307 million on March 31, 2022, and Decemb...
-
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at ...
-
Agenus ( NASDAQ: AGEN ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.22 (+40.5% Y/Y) and the consensus Revenue Estimate is $18.7M (+74.3% Y/Y). Over the last 3 months, EPS estimates have seen...
-
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference....
-
Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab Preclinical data support best-in-class potential of AGEN1571 LEXINGTON, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an im...
-
LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will release its second quarter 2022 financial results befor...
-
Agenus (NASDAQ: AGEN) opened at $2.65 then rose to a high of $2.93 in the early afternoon. The stock has a 52-week low of $1.25 and a 52-week high of $6.79. The pharmaceutical company focuses on finding therapies to treat cancer and infections by activating the body's immune respons...
-
It can be a lot of fun buying stocks trading in the single digits. While there are a lot of bad companies down in the cheap seats, sometimes you can find some amazing bargains. Our roundtable has found three really cool biotech stocks trading under $10 a share. Here's why we like SeaS...
Stock Information
MENU
AGEN
AGEN Quote
AGEN Short
AGEN News
AGEN Articles
Get AGEN Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
Ad
-
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q2 2022 Earnings Call Transcript
-
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at ...
-
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference....
x
Ad
